Arlene Smaldone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Arlene Smaldone has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Nancy S. Green
Columbia University
9 shared publications - Maureen George
Columbia University School of Nursing, New York, USA
8 shared publications - Andrea Cassells
Clinical Directors Network, New York, NY, United States
6 shared publications - Haomiao Jia
Columbia University
6 shared publications - Jonathan N. Tobin
Clinical Directors Network, New York, NY, United States
6 shared publications - Lena Mamykina
Columbia University, New York, NY, USA
6 shared publications
Latest Publications
- 28 May 2026
- Published by SAGE Publications in The Science of Diabetes Self-Management and Care
- Vol. 52 (4) , 353-365
Does Continuous Glucose Monitoring Improve Glycemic Control and Quality of Life Among Adults With Type 2 Diabetes in Primary Care Settings? A Systematic Review and Meta-Analysis
Purpose: The purpose of this systematic review and meta-analysis was to evaluate the impact of continuous glucose monitoring (CGM) on glycemic control and quality of life (QoL) among adults with type 2 diabetes (T2DM) managed within primary care settings. Methods: Following PRISMA 2020 guidelines, 4 databases were comprehensively searched for randomized controlled trials (RCTs) published through July 9, 2025. Eligible trials reported on A1C, QoL, diabetes distress, and device satisfaction. Shorter term (6-8 months) and longer term (12-14 months) A1C outcomes were synthesized using random effects meta-analysis models. Results: Of 739 records, 4 multisite RCTs (6 reports) met inclusion criteria and represent data from 566 adults with T2DM in primary care settings. Two trials utilized real time CGM, while others employed retrospective or intermittently scanned CGM. Participants attended primary care visits during the trial, receiving diabetes management and medication changes as required. The CGM intervention significantly improved glycemic control with pooled A1C reduction of −0.46% at 6 to 8 months and −0.33% at 12 to 14 months and device satisfaction with no differences in QoL. Conclusion: These results demonstrate that CGM significantly improves glycemic control with no change in QoL among adults with T2DM in primary care and suggest that CGM utilization within this setting offers distinct advantages in patient engagement and diabetes management, particularly when integrated through a multidisciplinary team approach. Future research should prioritize populations currently ineligible for CGM coverage, such as non-insulin-using patients and underserved groups, while also investigating the impact of updated sensors’ accuracy on clinical outcomes.
- 28 May 2026
- Published by SAGE Publications in The Science of Diabetes Self-Management and Care
- Vol. 52 (4) , 353-365
Does Continuous Glucose Monitoring Improve Glycemic Control and Quality of Life Among Adults With Type 2 Diabetes in Primary Care Settings? A Systematic Review and Meta-Analysis
Purpose: The purpose of this systematic review and meta-analysis was to evaluate the impact of continuous glucose monitoring (CGM) on glycemic control and quality of life (QoL) among adults with type 2 diabetes (T2DM) managed within primary care settings. Methods: Following PRISMA 2020 guidelines, 4 databases were comprehensively searched for randomized controlled trials (RCTs) published through July 9, 2025. Eligible trials reported on A1C, QoL, diabetes distress, and device satisfaction. Shorter term (6-8 months) and longer term (12-14 months) A1C outcomes were synthesized using random effects meta-analysis models. Results: Of 739 records, 4 multisite RCTs (6 reports) met inclusion criteria and represent data from 566 adults with T2DM in primary care settings. Two trials utilized real time CGM, while others employed retrospective or intermittently scanned CGM. Participants attended primary care visits during the trial, receiving diabetes management and medication changes as required. The CGM intervention significantly improved glycemic control with pooled A1C reduction of −0.46% at 6 to 8 months and −0.33% at 12 to 14 months and device satisfaction with no differences in QoL. Conclusion: These results demonstrate that CGM significantly improves glycemic control with no change in QoL among adults with T2DM in primary care and suggest that CGM utilization within this setting offers distinct advantages in patient engagement and diabetes management, particularly when integrated through a multidisciplinary team approach. Future research should prioritize populations currently ineligible for CGM coverage, such as non-insulin-using patients and underserved groups, while also investigating the impact of updated sensors’ accuracy on clinical outcomes.
- 3 February 2026
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 162, 108250
Impact of clinical trial virtualization on recruitment in underserved communities for a type 2 diabetes mHealth intervention
- 3 February 2026
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 162, 108250
Impact of clinical trial virtualization on recruitment in underserved communities for a type 2 diabetes mHealth intervention
- Open Access
Psycho-social and behavioral trends in Type 2 Diabetes self-management amongst medically underserved patients during the COVID-19 pandemic in an mHealth intervention
Objective To examine behavioral and psychosocial aspects of Type 2 Diabetes Mellitus (T2DM) self-management among medically underserved adults during the COVID-19 pandemic. Materials and Methods Baseline data were analyzed from T2 Coach, a randomized controlled trial testing a behavioral mHealth intervention using a conversational agent to support T2DM self-management. Participants (n=279) were recruited from Federally Qualified Health Centers in underserved areas of the New York City metropolitan area (2020–2023). Measures included demographics, HbA1c, BMI, mobile device proficiency, and validated surveys assessing self-care adherence (SCI-R), self-efficacy, diabetes distress (PAID), and pandemic-related experiences (e.g., food insecurity, dietary and exercise changes). Multiple linear regression models examined associations between demographic, clinical, and COVID-19-related variables with SCI-R, self-efficacy, PAID, and HbA1c outcomes. Results Participants were primarily female (60.6%), Hispanic (63.4%), and foreign-born (65.9%), with substantial socioeconomic disadvantage (43.7% Medicaid enrollment; 42.7% food insecurity). Mean HbA1c was 10.1 (SD 1.7). Pandemic-related disruptions were common: 18.7% ate more, 34.5% exercised less, and ∼40% changed food purchasing habits. Regression models indicated that poorer self-reported health and dietary changes were linked to higher distress and lower self-efficacy. Increased exercise predicted better adherence (higher SCI-R), and women demonstrated stronger adherence than men. Older age was associated with lower HbA1c. Digital literacy was not associated with self-management outcomes. Discussion COVID-19 exacerbated challenges to diabetes self-management among underserved populations, particularly through lifestyle disruptions and psychosocial stressors. Conclusion Findings underscore the need for culturally responsive, technology-enabled interventions that address diet, exercise, and emotional well-being to improve diabetes outcomes during public health crises.
Open AccessPsycho-social and behavioral trends in Type 2 Diabetes self-management amongst medically underserved patients during the COVID-19 pandemic in an mHealth intervention
Objective To examine behavioral and psychosocial aspects of Type 2 Diabetes Mellitus (T2DM) self-management among medically underserved adults during the COVID-19 pandemic. Materials and Methods Baseline data were analyzed from T2 Coach, a randomized controlled trial testing a behavioral mHealth intervention using a conversational agent to support T2DM self-management. Participants (n=279) were recruited from Federally Qualified Health Centers in underserved areas of the New York City metropolitan area (2020–2023). Measures included demographics, HbA1c, BMI, mobile device proficiency, and validated surveys assessing self-care adherence (SCI-R), self-efficacy, diabetes distress (PAID), and pandemic-related experiences (e.g., food insecurity, dietary and exercise changes). Multiple linear regression models examined associations between demographic, clinical, and COVID-19-related variables with SCI-R, self-efficacy, PAID, and HbA1c outcomes. Results Participants were primarily female (60.6%), Hispanic (63.4%), and foreign-born (65.9%), with substantial socioeconomic disadvantage (43.7% Medicaid enrollment; 42.7% food insecurity). Mean HbA1c was 10.1 (SD 1.7). Pandemic-related disruptions were common: 18.7% ate more, 34.5% exercised less, and ∼40% changed food purchasing habits. Regression models indicated that poorer self-reported health and dietary changes were linked to higher distress and lower self-efficacy. Increased exercise predicted better adherence (higher SCI-R), and women demonstrated stronger adherence than men. Older age was associated with lower HbA1c. Digital literacy was not associated with self-management outcomes. Discussion COVID-19 exacerbated challenges to diabetes self-management among underserved populations, particularly through lifestyle disruptions and psychosocial stressors. Conclusion Findings underscore the need for culturally responsive, technology-enabled interventions that address diet, exercise, and emotional well-being to improve diabetes outcomes during public health crises.
- Open Access
Impact of Clinical Trial Virtualization on Recruitment in Underserved Communities for a Type 2 Diabetes mHealth Intervention
Objective Approaches to randomized clinical trial (RCT) implementation greatly changed during the COVID-19 pandemic as clinical trials transitioned to largely virtual implementation; virtual RCT implementation may continue in the future. Without careful consideration, virtual RCTs may exacerbate the historical under-representation of women, the elderly, and racial and ethnic minorities that has occurred in past clinical trials. The following study presents an approach to virtualizing an RCT for an mHealth intervention. Materials and Methods Participants for the trial were recruited from Federally Qualified Health Centers in medically underserved areas of the New York City metropolitan area. Recruitment began in January 2020 but was paused in March 2020 due to the COVID-19 pandemic’s onset. The research team developed a virtual protocol for recruitment, onboarding, and study implementation. Results Study participants were predominantly from immigrant, low-income, and racial and ethnic minority groups. Our virtualization approach included an easier-to-understand consent form, expanded virtual training materials, and greater one-on-one attention during training. Our approach did not lead to significant changes in the population we recruited into the study or introduce additional biases and restriction. Discussion Our study represents an early investigation into how the change from in-person clinical trial recruitment and study implementation to virtual during the COVID-19 pandemic may impact recruitment of participants from medically underserved communities into RCTs. Conclusion This approach may be used in future trials testing mHealth and other technological interventions without exacerbating the under-representation of medically underserved populations. Highlights The COVID-19 pandemic accelerated the shift to virtual randomized clinical trials (RCTs), raising concerns about exacerbating the under-representation of marginalized groups. This study implemented a fully virtual RCT for a mHealth intervention with consideration of inclusivity. Participants were recruited from Federally Qualified Health Centers in medically underserved areas of New York City, with most coming from immigrant, low-income, and minority communities. Adaptations such as simplified consent, expanded virtual training, and individualized support ensured accessibility without altering participant demographics or introducing bias, providing a replicable model for equitable virtual trials.
Open AccessImpact of Clinical Trial Virtualization on Recruitment in Underserved Communities for a Type 2 Diabetes mHealth Intervention
Objective Approaches to randomized clinical trial (RCT) implementation greatly changed during the COVID-19 pandemic as clinical trials transitioned to largely virtual implementation; virtual RCT implementation may continue in the future. Without careful consideration, virtual RCTs may exacerbate the historical under-representation of women, the elderly, and racial and ethnic minorities that has occurred in past clinical trials. The following study presents an approach to virtualizing an RCT for an mHealth intervention. Materials and Methods Participants for the trial were recruited from Federally Qualified Health Centers in medically underserved areas of the New York City metropolitan area. Recruitment began in January 2020 but was paused in March 2020 due to the COVID-19 pandemic’s onset. The research team developed a virtual protocol for recruitment, onboarding, and study implementation. Results Study participants were predominantly from immigrant, low-income, and racial and ethnic minority groups. Our virtualization approach included an easier-to-understand consent form, expanded virtual training materials, and greater one-on-one attention during training. Our approach did not lead to significant changes in the population we recruited into the study or introduce additional biases and restriction. Discussion Our study represents an early investigation into how the change from in-person clinical trial recruitment and study implementation to virtual during the COVID-19 pandemic may impact recruitment of participants from medically underserved communities into RCTs. Conclusion This approach may be used in future trials testing mHealth and other technological interventions without exacerbating the under-representation of medically underserved populations. Highlights The COVID-19 pandemic accelerated the shift to virtual randomized clinical trials (RCTs), raising concerns about exacerbating the under-representation of marginalized groups. This study implemented a fully virtual RCT for a mHealth intervention with consideration of inclusivity. Participants were recruited from Federally Qualified Health Centers in medically underserved areas of New York City, with most coming from immigrant, low-income, and minority communities. Adaptations such as simplified consent, expanded virtual training, and individualized support ensured accessibility without altering participant demographics or introducing bias, providing a replicable model for equitable virtual trials.
- Open Access
- 26 August 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (11) , e31990
HABIT Efficacy Trial Intervention Improves Elements of General and Disease‐Specific Quality of Life in Youth With Sickle Cell Disease
Background: Whether interventions to improve hydroxyurea adherence in youth with sickle cell disease (SCD) also improve health‐related quality of life (HRQoL) has not been determined. We prospectively examined changes in generic and disease‐specific HRQoL over a 12‐month period in youth who participated in “Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment (HABIT)” randomized controlled multi‐site efficacy trial. The HABIT intervention was led by community health workers and augmented by tailored text message reminders.Methods: Improvements in generic and disease‐specific HRQoL were secondary HABIT outcomes. Intervention efficacy and sustainability were measured as changes in HRQoL from Months 0 to 9 and from Months 9 to 12 of the trial, respectively. Data were analyzed for within‐group and between‐group changes.Results: Fifty youth, 24 assigned to intervention and 26 to the control group, mean age of 13.3 ± 1.9 years, participated in the trial. There were no differences between groups at study entry. At Month 0, total generic and disease‐specific HRQoL scores were 71.2 ± 15.6 and 62.7 ± 19.0, respectively. At 9 months, compared to controls, the intervention group significantly improved generic HRQoL total score (p = 0.04) and two subscales (emotional, p = 0.03, and social, p = 0.01), and one disease‐specific HRQoL subscale (treatment, p = 0.006). HRQoL improvements were not sustained at 12 months.Conclusions: Findings of this study contribute to the evolving understanding of the impact of interventions to improve hydroxyurea adherence on HRQoL in youth with SCD. Further research directed to enhancing intervention sustainability is needed to maintain hydroxyurea adherence and HRQoL improvements to reduce health disparities for youth with SCD.
- 26 August 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (11) , e31990
Open AccessHABIT Efficacy Trial Intervention Improves Elements of General and Disease‐Specific Quality of Life in Youth With Sickle Cell Disease
Background: Whether interventions to improve hydroxyurea adherence in youth with sickle cell disease (SCD) also improve health‐related quality of life (HRQoL) has not been determined. We prospectively examined changes in generic and disease‐specific HRQoL over a 12‐month period in youth who participated in “Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment (HABIT)” randomized controlled multi‐site efficacy trial. The HABIT intervention was led by community health workers and augmented by tailored text message reminders.Methods: Improvements in generic and disease‐specific HRQoL were secondary HABIT outcomes. Intervention efficacy and sustainability were measured as changes in HRQoL from Months 0 to 9 and from Months 9 to 12 of the trial, respectively. Data were analyzed for within‐group and between‐group changes.Results: Fifty youth, 24 assigned to intervention and 26 to the control group, mean age of 13.3 ± 1.9 years, participated in the trial. There were no differences between groups at study entry. At Month 0, total generic and disease‐specific HRQoL scores were 71.2 ± 15.6 and 62.7 ± 19.0, respectively. At 9 months, compared to controls, the intervention group significantly improved generic HRQoL total score (p = 0.04) and two subscales (emotional, p = 0.03, and social, p = 0.01), and one disease‐specific HRQoL subscale (treatment, p = 0.006). HRQoL improvements were not sustained at 12 months.Conclusions: Findings of this study contribute to the evolving understanding of the impact of interventions to improve hydroxyurea adherence on HRQoL in youth with SCD. Further research directed to enhancing intervention sustainability is needed to maintain hydroxyurea adherence and HRQoL improvements to reduce health disparities for youth with SCD.
- Open Access
- 12 August 2025
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e82305
Promoting Problem-Solving Among Low-Income Adults with Type 2 Diabetes: A Cluster-Randomized Controlled Trial of Mobile Diabetes Detective, an mHealth Intervention with Text Messaging (Preprint)
Problem-solving is essential for the self-management of type 2 diabetes but remains challenging for underserved individuals. Although mobile health (mHealth) interventions can improve diabetes self-management, few focus on problem-solving. This study evaluates the efficacy of Mobile Diabetes Detective (MoDD), a fully automated web-based intervention with SMS text messaging that provides problem-solving support tailored to self-monitoring data, for improving glycemic control among medically underserved adults with type 2 diabetes. This open-label, 1:1 cluster-randomized controlled trial was conducted in 2013-2018. Participants were adults with type 2 diabetes (glycated hemoglobin [HbA1c] >7.5%) receiving care at 8 Federally Qualified Health Centers serving medically underserved communities in the New York metropolitan area. The centers served as clusters and were randomized using computer-generated allocation. Recruitment and study sessions were conducted either in person or in a hybrid format. The intervention arm used MoDD for 12 months, whereas the control arm received standard diabetes education and routine care. The primary outcome was the change in HbA1c from baseline to 12 months, recorded from medical chart data. We hypothesized greater improvement in the intervention arm than in the control arm. Secondary outcomes included psychosocial measures. Outcomes were compared between groups using intention-to-treat analyses. This report presents the final analysis of the outcomes. This trial randomized 248 participants (intervention arm: n=126; control arm: n=122); 219 were included in the final analysis (intervention arm: n=111; control arm: n=108). Participants were predominantly female (147/219, 67.1%) and ethnically and racially diverse (112/219, 51.1%, Hispanic and 92/219, 42%, African American), with a mean baseline HbA1c of 9.9%. Overall, of the 111 participants, 44 (39.6%) engaged with MoDD at least once weekly in the first 30 days, and 22 (19.8%) engaged at least once weekly in the first 90 days. HbA1c did not differ significantly between groups at baseline (intervention: 9.81%, 95% CI 9.42%-10.20%; control: 9.95%, 95% CI 9.55%-10.34%; difference=0.14%, P=.63) or at 12 months (intervention: 9.36%, 95% CI 8.95%-9.78%; control: 9.58%, 95% CI 9.15%-10.01%; difference=-0.22%, P=.47). Both groups demonstrated reductions in HbA1c from baseline to 3 months. Sustained within-group improvement at 12 months was observed in the intervention group but not in the control group. No intervention-related adverse events were reported. This study evaluated the impact of a mobile intervention for problem-solving in diabetes. MoDD is innovative because it operates autonomously and tailors support to individuals' self-monitoring data. Although there was no significant between-group difference in HbA1c, the intervention group showed sustained within-group improvement at 12 months. These findings highlight the potential long-term benefits of autonomous mHealth interventions for problem-solving. The study observed an increase in diabetes distress, possibly reflecting heightened awareness of uncontrolled blood glucose levels. If implemented in clinical practice, MoDD could complement diabetes education and help improve glycemic control. ClinicalTrials.gov NCT02021591; https://clinicaltrials.gov/ct2/show/NCT02021591.
- 12 August 2025
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e82305
Open AccessPromoting Problem-Solving Among Low-Income Adults with Type 2 Diabetes: A Cluster-Randomized Controlled Trial of Mobile Diabetes Detective, an mHealth Intervention with Text Messaging (Preprint)
Problem-solving is essential for the self-management of type 2 diabetes but remains challenging for underserved individuals. Although mobile health (mHealth) interventions can improve diabetes self-management, few focus on problem-solving. This study evaluates the efficacy of Mobile Diabetes Detective (MoDD), a fully automated web-based intervention with SMS text messaging that provides problem-solving support tailored to self-monitoring data, for improving glycemic control among medically underserved adults with type 2 diabetes. This open-label, 1:1 cluster-randomized controlled trial was conducted in 2013-2018. Participants were adults with type 2 diabetes (glycated hemoglobin [HbA1c] >7.5%) receiving care at 8 Federally Qualified Health Centers serving medically underserved communities in the New York metropolitan area. The centers served as clusters and were randomized using computer-generated allocation. Recruitment and study sessions were conducted either in person or in a hybrid format. The intervention arm used MoDD for 12 months, whereas the control arm received standard diabetes education and routine care. The primary outcome was the change in HbA1c from baseline to 12 months, recorded from medical chart data. We hypothesized greater improvement in the intervention arm than in the control arm. Secondary outcomes included psychosocial measures. Outcomes were compared between groups using intention-to-treat analyses. This report presents the final analysis of the outcomes. This trial randomized 248 participants (intervention arm: n=126; control arm: n=122); 219 were included in the final analysis (intervention arm: n=111; control arm: n=108). Participants were predominantly female (147/219, 67.1%) and ethnically and racially diverse (112/219, 51.1%, Hispanic and 92/219, 42%, African American), with a mean baseline HbA1c of 9.9%. Overall, of the 111 participants, 44 (39.6%) engaged with MoDD at least once weekly in the first 30 days, and 22 (19.8%) engaged at least once weekly in the first 90 days. HbA1c did not differ significantly between groups at baseline (intervention: 9.81%, 95% CI 9.42%-10.20%; control: 9.95%, 95% CI 9.55%-10.34%; difference=0.14%, P=.63) or at 12 months (intervention: 9.36%, 95% CI 8.95%-9.78%; control: 9.58%, 95% CI 9.15%-10.01%; difference=-0.22%, P=.47). Both groups demonstrated reductions in HbA1c from baseline to 3 months. Sustained within-group improvement at 12 months was observed in the intervention group but not in the control group. No intervention-related adverse events were reported. This study evaluated the impact of a mobile intervention for problem-solving in diabetes. MoDD is innovative because it operates autonomously and tailors support to individuals' self-monitoring data. Although there was no significant between-group difference in HbA1c, the intervention group showed sustained within-group improvement at 12 months. These findings highlight the potential long-term benefits of autonomous mHealth interventions for problem-solving. The study observed an increase in diabetes distress, possibly reflecting heightened awareness of uncontrolled blood glucose levels. If implemented in clinical practice, MoDD could complement diabetes education and help improve glycemic control. ClinicalTrials.gov NCT02021591; https://clinicaltrials.gov/ct2/show/NCT02021591.
- Open Access
- 12 August 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Promoting Problem-Solving Among Low-Income Adults with Type 2 Diabetes: A Cluster-Randomized Trial of Mobile Diabetes Detective (Preprint)
BACKGROUND Problem-solving skills are essential to the successful management of type 2 diabetes but challenging to develop for low-resource medically underserved individuals. mHealth interventions have shown positive impact on diabetes management but few focus specifically on problem-solving. OBJECTIVE To evaluate the efficacy of an mHealth intervention, Mobile Diabetes Detective (MoDD), for facilitating problem-solving and self-care among underserved adults with type 2 diabetes. METHODS This cluster-randomized non-blinded clinical trial included 219 participants with type 2 diabetes (HbA1c > 7.5%) from 8 Federally Qualified Health Centers that serve low-resource communities. The intervention arm (n=111) used MoDD for 4 weeks and up to 1 year. The control arm (n=108) received standard diabetes education and usual care. The primary hypotheses were improvement in HbA1c, diabetes problem-solving abilities, and diabetes self-care behaviors from baseline to 4 weeks, 3 months, and 12 months. Secondary hypotheses were improvement in diabetes self-efficacy and diabetes distress. Data were analyzed for both within group change and between group differences at each study milestone. RESULTS Participants (n=219) were predominantly female (67%), ethnically and racially diverse (51% Hispanic, 42% African American), with mean glycated hemoglobin HbA1c=9.9% at baseline. There was no change in HbA1c at 4 weeks in either arm; both arms reduced HbA1c from baseline to 3 months (intervention: -0.58% (p=0.005); control: -1.03% (p<0.001)); only the intervention arm reduced HbA1c from baseline to 12 months (intervention: -0.45% (p=0.01); control: -0.37% (p=0.047). There was no improvement in diabetes problem-solving, and mixed results in diabetes self-care behaviors. Both arms improved diabetes self-efficacy at 3 and 12 months; the intervention arm reported increase in diabetes distress at 3 and 12 months. The only difference in outcomes between study arms was in following a diabetes-specific diet at 12 months with the control arm reporting higher adherence (intervention: 4.48, control: 5.17, p=0.004). CONCLUSIONS All participants improved blood glucose management at 3 months but only the intervention arm sustained improvement over time; there was no change in diabetes problem solving abilities. These findings suggest potential benefits of using mHealth interventions for underserved individuals with type 2 diabetes and the need for further research on improving problem-solving with mHealth. CLINICALTRIAL NCT02021591
- 12 August 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessPromoting Problem-Solving Among Low-Income Adults with Type 2 Diabetes: A Cluster-Randomized Trial of Mobile Diabetes Detective (Preprint)
BACKGROUND Problem-solving skills are essential to the successful management of type 2 diabetes but challenging to develop for low-resource medically underserved individuals. mHealth interventions have shown positive impact on diabetes management but few focus specifically on problem-solving. OBJECTIVE To evaluate the efficacy of an mHealth intervention, Mobile Diabetes Detective (MoDD), for facilitating problem-solving and self-care among underserved adults with type 2 diabetes. METHODS This cluster-randomized non-blinded clinical trial included 219 participants with type 2 diabetes (HbA1c > 7.5%) from 8 Federally Qualified Health Centers that serve low-resource communities. The intervention arm (n=111) used MoDD for 4 weeks and up to 1 year. The control arm (n=108) received standard diabetes education and usual care. The primary hypotheses were improvement in HbA1c, diabetes problem-solving abilities, and diabetes self-care behaviors from baseline to 4 weeks, 3 months, and 12 months. Secondary hypotheses were improvement in diabetes self-efficacy and diabetes distress. Data were analyzed for both within group change and between group differences at each study milestone. RESULTS Participants (n=219) were predominantly female (67%), ethnically and racially diverse (51% Hispanic, 42% African American), with mean glycated hemoglobin HbA1c=9.9% at baseline. There was no change in HbA1c at 4 weeks in either arm; both arms reduced HbA1c from baseline to 3 months (intervention: -0.58% (p=0.005); control: -1.03% (p<0.001)); only the intervention arm reduced HbA1c from baseline to 12 months (intervention: -0.45% (p=0.01); control: -0.37% (p=0.047). There was no improvement in diabetes problem-solving, and mixed results in diabetes self-care behaviors. Both arms improved diabetes self-efficacy at 3 and 12 months; the intervention arm reported increase in diabetes distress at 3 and 12 months. The only difference in outcomes between study arms was in following a diabetes-specific diet at 12 months with the control arm reporting higher adherence (intervention: 4.48, control: 5.17, p=0.004). CONCLUSIONS All participants improved blood glucose management at 3 months but only the intervention arm sustained improvement over time; there was no change in diabetes problem solving abilities. These findings suggest potential benefits of using mHealth interventions for underserved individuals with type 2 diabetes and the need for further research on improving problem-solving with mHealth. CLINICALTRIAL NCT02021591
- Open Access
- 25 April 2025
- Published by Association for Computing Machinery (ACM)
- Vol. 2025, 1-17
T2 Coach: A Qualitative Study of an Automated Health Coach for Diabetes Self-Management
Computational intelligence is increasingly common in interactive systems in many domains, including health. Health coaching with conversational agents (CA) can reach wide populations, but the level of computational intelligence needed for a positive coaching experience is unclear. We conducted a study with sixteen individuals with diabetes and prediabetes who used a CA for health coaching, T2 Coach. Qualitative interviews revealed that participants saw T2 Coach as reliable in helping them stay on track with self-management, appreciated the flexibility in choosing personally meaningful goals and engaging on their own terms, and felt it provided encouragement and even compared it favorably with human coaches. However, they also noted that coaching experience could be improved with more fluid conversations, more tailoring to their personal preferences and lifestyles, and more sensitivity to specific contexts, all of which require more computational intelligence. We discuss implications and design directions for more intelligent coaching CA in health.
- 25 April 2025
- Published by Association for Computing Machinery (ACM)
- Vol. 2025, 1-17
Open AccessT2 Coach: A Qualitative Study of an Automated Health Coach for Diabetes Self-Management
Computational intelligence is increasingly common in interactive systems in many domains, including health. Health coaching with conversational agents (CA) can reach wide populations, but the level of computational intelligence needed for a positive coaching experience is unclear. We conducted a study with sixteen individuals with diabetes and prediabetes who used a CA for health coaching, T2 Coach. Qualitative interviews revealed that participants saw T2 Coach as reliable in helping them stay on track with self-management, appreciated the flexibility in choosing personally meaningful goals and engaging on their own terms, and felt it provided encouragement and even compared it favorably with human coaches. However, they also noted that coaching experience could be improved with more fluid conversations, more tailoring to their personal preferences and lifestyles, and more sensitivity to specific contexts, all of which require more computational intelligence. We discuss implications and design directions for more intelligent coaching CA in health.
- 8 July 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (9) , e31170
Assessing multilevel barriers to hydroxyurea adherence in youth with sickle cell disease using pharmacy‐based refill records
Background: Suboptimal medication adherence is common across youth with chronic health conditions and may contribute to health disparities and adverse health outcomes, especially in underserved communities.Methods: Using pharmacy prescription records and guided by the World Health Organization Multidimensional Adherence Model, we examined patient‐, treatment‐, and health system–related factors that may affect hydroxyurea adherence in 72 youth with sickle cell disease (SCD), 10‐18 years who had participated in the multisite “Hydroxyurea Adherence for Personal Best in SCD” (HABIT) feasibility (6 months) and efficacy (12 months) trials. Pharmacy data were collected from the year prior to study entry through the duration of each trial. We also examined hydroxyurea dose at baseline, prescribing patterns (hydroxyurea formulation and dose prescribed), quantity of hydroxyurea dispensed, and number of daily capsules/tablets prescribed. Data were analyzed using descriptive statistics.Results: On average, youth were prescribed 1095 ± 402 mg hydroxyurea per day, requiring ingestion of 3 or more capsules for 39.4% of youth. Frequently identified potential barriers were complex medication regimens in which dose of hydroxyurea differed by day of week (47.2%); receipt of an inadequate (< 30 days) supply of hydroxyurea from the pharmacy ≥ 3 times during record collection period (29.2%); and prescription of hydroxyurea suspension suggesting problems swallowing capsules (22.2%). In this sample, most youth were exclusively prescribed 500 mg capsules (62.5%), which was associated with complex medication regimens (RR 3.0, 95% CI 1.4‐6.7). Potential barriers were common, occurred at all levels and are potentially modifiable with targeted interventions at the treatment‐ and health system–related levels.
- 8 July 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (9) , e31170
Assessing multilevel barriers to hydroxyurea adherence in youth with sickle cell disease using pharmacy‐based refill records
Background: Suboptimal medication adherence is common across youth with chronic health conditions and may contribute to health disparities and adverse health outcomes, especially in underserved communities.Methods: Using pharmacy prescription records and guided by the World Health Organization Multidimensional Adherence Model, we examined patient‐, treatment‐, and health system–related factors that may affect hydroxyurea adherence in 72 youth with sickle cell disease (SCD), 10‐18 years who had participated in the multisite “Hydroxyurea Adherence for Personal Best in SCD” (HABIT) feasibility (6 months) and efficacy (12 months) trials. Pharmacy data were collected from the year prior to study entry through the duration of each trial. We also examined hydroxyurea dose at baseline, prescribing patterns (hydroxyurea formulation and dose prescribed), quantity of hydroxyurea dispensed, and number of daily capsules/tablets prescribed. Data were analyzed using descriptive statistics.Results: On average, youth were prescribed 1095 ± 402 mg hydroxyurea per day, requiring ingestion of 3 or more capsules for 39.4% of youth. Frequently identified potential barriers were complex medication regimens in which dose of hydroxyurea differed by day of week (47.2%); receipt of an inadequate (< 30 days) supply of hydroxyurea from the pharmacy ≥ 3 times during record collection period (29.2%); and prescription of hydroxyurea suspension suggesting problems swallowing capsules (22.2%). In this sample, most youth were exclusively prescribed 500 mg capsules (62.5%), which was associated with complex medication regimens (RR 3.0, 95% CI 1.4‐6.7). Potential barriers were common, occurred at all levels and are potentially modifiable with targeted interventions at the treatment‐ and health system–related levels.
- 31 May 2024
- Published by Springer Nature
- p. 551-564
Psychosocial and Educational Implications of Diabetic Foot Complications
- 31 May 2024
- Published by Springer Nature
- p. 551-564
Psychosocial and Educational Implications of Diabetic Foot Complications